July 18, 2016: Iron Horse Diagnostics announces a non-exclusive license agreement with Euroimmun AG to launch clinical assays for neurofilament proteins and the first biologic diagnostic test for ALS in hospitals throughout Europe. Full media release: http://ironhorsedx.com/wp-content/uploads/2016/07/press-release-final.pdf
March 2016: Iron Horse Diagnostics was given the People’s Choice Award and presented a check for $5,000 at the 2016 Annual Invest Southwest Venture Madness competition.
January 2016: Iron Horse Diagnostics received a $200,000 grant from the national ALS Association for the ongoing validation of our ALS diagnostic test in 300 subjects from the US and Europe. The ALSA grant comes from money raised during the 2014 ALS Ice Bucket Challenge.
May 26, 2015: Robert P. Bowser PhD honored by The American Academy of Neurology and The ALS Association: http://www.azbio.org/robert-p-bowser-phd-honored-by-the-american-academy-of-neurology-and-the-als-association
April 3, 2015: Arizona researcher on path to bring world’s first ALS diagnostic test to market: http://www2.azcommerce.com/tech-connect/bioscience-health/2015/4/3/als-iron-horse-diagnostics
March 12, 2015: Founder Robert Bowser was awarded the 2015 Sheila Essey Award for ALS Research: http://www.alsa.org/news/archive/2015-essey-award.html
January 28, 2015: Iron Horse Dx wins Arizona Commerce Authority Innovation Challenge: Iron Horse Press Release_ACA (2)
August 27, 2014: Iron Horse Diagnostics was awarded a NIH Phase II small business grant to complete clinical validation and commercialization of its ALS diagnostic test.
August 22, 2014: Iron Horse Diagnostics was selected to present at the White Hat Life Science Investor Conference in Phoenix, AZ that will occur on September 18, 2014.
June 30, 2014: Iron Horse Diagnostics successfully completed all milestones for its NIH Phase I small business grant.
May 19, 2014: Iron Horse Diagnostics was among academic and industry leasers invited to attend and present at an ALS biomarkers summit held in Boston, MA. Iron Horse presented data on its CLIA certified assays for neurofilament and complement c3 proteins.
December 1, 2013: Andreas Jeromin, Ph.D. has been appointed Chief Scientific Officer of Iron Horse Diagnostics.
October 23, 2013: Iron Horse Diagnostics announces a partnership with Biogen Idec to accelerate the development of the ALS diagnostic. Biogen Idec is a biotechnology company headquartered in Boston, MA that specialize in drugs of neurologic disorders, with a portfolio in ALS. Biogen Idec will provide Iron Horse Diagnostics non-diluting capital to help fund late stage development of a diagnostic test for ALS.
October 1, 2013: Iron Horse Diagnostics was highlighted as a start-up medial device and Diagnostics company by MedCity News: http://research.medcitynews.com/files/2013/11/MedCity-Startup-Report-October-20131.pdf
Iron Horse Diagnostics was awarded a small business grant (STTR) from the National Institutes of Health on September 1, 2013. This Fast Track phase I/phase II STTR has a total funding of 1.2 million dollars and will help fund the validation of the ALS diagnostic test in 6 clinic sites in the US and Europe.
July 12, 2013: Iron Horse Diagnostics partnership for ALS diagnostics on the horizon: http://www.azbio.org/iron-horse-dx-biopharm-insight
Iron Horse Diagnostics was a recipient of the 2013 AZ Bio Fast Lane Award from the Arizona Bioindustry Association: http://www.highbeam.co/doc/1G1-343582929.html
ALS diagnostic test described in Phoenix Business Journal on May 25, 2012: http://www.bizjournals.com/phoenix/print-edition/2012/05/25/researcher-develops-tool-to-more.html
Arizona annual Bioindustry Association presentation by Dr. Bowser: http://www.prweb.com/releases/2012/5/prweb9479686.htm
The December, 2011 issue of the Barrow magazine describes the recruitment of Dr. Bowser to Barrow Neurological Institute and formation of Gregory W. Fulton ALS Research Center: http://issuu.com/barrow/docs/barrowmagazinevol23issue2